about
Animal models of myasthenia gravis: utility and limitationsEvolution of animal models in cancer vaccine developmentExtracorporeal whole blood immunoadsorption of autoimmune myasthenia gravis by cellulose tryptophan adsorbentRNA expression analysis of passive transfer myasthenia supports extraocular muscle as a unique immunological environment.Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: a human and animal model studyAcetylcholine receptor-alpha subunit expression in myasthenia gravis: a role for the autoantigen in pathogenesis?CD1d(hi)CD5+ B cells expanded by GM-CSF in vivo suppress experimental autoimmune myasthenia gravis.Extraocular muscle characteristics related to myasthenia gravis susceptibility.Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice.Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patientsIgG1 deficiency exacerbates experimental autoimmune myasthenia gravis in BALB/c miceGM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravisExperimental autoimmune myasthenia gravis in the mouse.How clinical trials of myasthenia gravis can inform pre-clinical drug developmentImmunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease."Warming yang and invigorating qi" acupuncture alters acetylcholine receptor expression in the neuromuscular junction of rats with experimental autoimmune myasthenia gravisProspects for a T-cell receptor vaccination against myasthenia gravis.A comparison of epitope repertoires associated with myasthenia gravis in humans and nonhuman hosts.Biomarker development for myasthenia gravisEstrogen-mediated downregulation of AIRE influences sexual dimorphism in autoimmune diseases.Strategies for treating autoimmunity: novel insights from experimental myasthenia gravisHer-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity.Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes.Combining human and rat sequences in her-2 DNA vaccines blunts immune tolerance and drives antitumor immunity.Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?Recommendations for myasthenia gravis clinical trials.Novel animal models of acetylcholine receptor antibody-related myasthenia gravis.Animal models for metabolic, neuromuscular and ophthalmological rare diseases.Animal models of antimuscle-specific kinase myasthenia.Rapamycin alleviates inflammation and muscle weakness, while altering the Treg/Th17 balance in a rat model of myasthenia gravis.In vitro characterization of an acetylcholine receptor-transferrin fusion protein for the treatment of myasthenia gravis.Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis.Myasthenia gravis: the role of complement at the neuromuscular junction.Engineered agrin attenuates the severity of experimental autoimmune myasthenia gravis.
P2860
Q26750632-F6E4429B-CDE2-47A9-8B16-7FAAD76996F3Q28080739-EC8B9530-4275-4CD1-90A3-B5B75BDC6E76Q28258023-0D3C0F67-9C1E-4784-89CA-7CAED19B235AQ33915924-AE085464-8623-454E-A92A-E7F47F5FF452Q33933202-1EA9914A-C9C9-441F-BADC-64768801DA7FQ34079029-953A52BD-F03A-440F-81A9-FAD6FFD558A3Q34204228-4C8FD2DE-DD03-4A0D-838D-4FFCC08F4D6CQ34586123-DE944A2E-BF9D-4874-81F8-A93CDD3571D8Q34790901-B5639580-6968-426A-9D99-08B823349703Q35279680-F4764B94-1E6A-46E7-B822-72FD40A5D605Q35400161-115BA5F1-5EB2-4FCD-8DF9-EF85B3512821Q35603050-0ED85AC3-58B2-4947-9D29-0147E2BD7956Q35644910-5C61361B-7B21-4C94-9AFE-9166C0EAC527Q35738870-A968987E-8104-42E6-B759-9A1F3618E86EQ35994774-79407FC4-C1A0-4B26-BAFC-2449BE61DAADQ36002769-C659D414-7BCC-4C00-9805-3A68D79D9905Q36238694-AFA9D1FD-388F-4414-82CF-93F137C2A2F9Q36455616-062FFACA-19EB-4740-9A1E-3FA806750C26Q36515375-91F5E8E8-13D0-4F49-8EE4-56AD4701AE2FQ36737968-6E8445DC-37CB-413C-B5AA-A48A61E555EFQ37099096-7063C7F5-6896-47A1-89C0-59613272B400Q37307584-48311262-E1DB-4CC1-9472-43E1C8024BC9Q37561515-073850DC-D783-41A0-BA14-D46F23CBBA7DQ37626805-02D86886-3E23-4B26-BAD0-A893262B8DD0Q37967185-9BCF5F75-33BC-4421-9157-0E9D02BB7C75Q38009753-DCE831F7-32A7-4685-B703-DFCFA9DA1929Q38068536-D4DA5039-8D90-46FF-9B9E-551D5EEEA7CCQ38089518-664AE6E6-0A76-4510-8BD7-5CAEA8873256Q41846302-7739ABF5-A435-4126-9CA4-0F55D3A839B2Q42334836-5568491D-597E-42A6-B116-7D8898D47AE5Q43093968-312A91B2-E257-4E53-A919-913170A36149Q43279093-03E697DD-9DEC-4869-A813-4F47DFBFE717Q47266287-DF54218D-6DF5-425F-8F4F-4F73A36C67D4Q47570833-70AFF231-5BF9-4F62-A070-D1CDB75EA629
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Animal models of myasthenia gravis.
@ast
Animal models of myasthenia gravis.
@en
type
label
Animal models of myasthenia gravis.
@ast
Animal models of myasthenia gravis.
@en
prefLabel
Animal models of myasthenia gravis.
@ast
Animal models of myasthenia gravis.
@en
P2093
P356
P1433
P1476
Animal models of myasthenia gravis.
@en
P2093
P356
10.1006/CLIM.1999.4807
P577
2000-02-01T00:00:00Z